Session Information
Date: Sunday, October 7, 2018
Session Title: Parkinsonism, MSA, PSP (Secondary and Parkinsonism-Plus)
Session Time: 1:45pm-3:15pm
Location: Hall 3FG
Objective: To evaluate diagnostic and prognostic usefulness of a panel of CSF biomarkers in PSP patients presenting with Richardson’s Syndrome (RS).
Background: PSP is a heterogeneous clinical-pathological entity still lacking effective disease biomarkers. CSF levels of total-tau (t-tau), phosphorylated-tau (p-tau), 42-beta-amyloid (Ab42), and derived Ab42/p-tau and p-tau/t-tau ratios mirror neuropathological changes and are currently used to improve early differential diagnosis and prognostic clustering of patients with neurodegenerative disorders.
Methods: CSF levels of t-tau, p-tau, Ab42, Ab42/p-tau and p-tau/t-tau ratios were comparatively evaluated in 39 PSP patients, 31 patients with Parkinson’s Disease (PD) and 58 gender/age-matched healthy controls (CTL). Demographic and clinical data together with specific gold-standard clinical scores (MMSE, PSP Rating Scale and UPDRS part 3) were obtained for enrolled subjects. Parametric and non-parametric tests were conducted to evaluate differences among the groups. The ROC curve analysis with cut-off point calculation was further run. Spearman’ test and subsequent linear regression analysis (using age and gender as covariates) were applied to test the association between biomarkers and clinical scores in PSP.
Results: In PSP, Ab42 was lower than CTL and PD; t-tau and p-tau were instead both reduced compared to CTL but not to PD. At the cut-off value of 623 pg/ml, Ab42 distinguishes PSP from CTL and PD with the highest accuracy. The p-tau/t-tau ratio (cut-off=0.185) allows the differential diagnosis between PSP and PD. Ab42 was inversely associated with PSP-Rating Scale total score, independently from age and gender.
Conclusions: CSF Ab42 levels may reflect widespread neurodegeneration occurring in PSP. Therefore, it could represent a potential biomarker either for diagnosing or estimating clinical severity in PSP patients presenting with RS. Moreover, the p-tau/t-tau ratio seems to support the early differential diagnosis versus PD.
To cite this abstract in AMA style:
T. Schirinzi, G. Sancesario, G. Di Lazzaro, N. Mercuri, S. Bernardini, A. Lang, A. Pisani. Assessment of CSF biomarkers clinical value in Progressive Supranuclear Palsy [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/assessment-of-csf-biomarkers-clinical-value-in-progressive-supranuclear-palsy/. Accessed May 17, 2025.« Back to 2018 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/assessment-of-csf-biomarkers-clinical-value-in-progressive-supranuclear-palsy/